logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Syros Pharmaceuticals, Inc.


USPTO Granted Patents = 24

% Expired Patents = 16.7



Trademarks = 2

Forward Citations = 61

Loading Chart...
Loading Chart...

54 inventors (with patents filed for the assignee):

goldMedal Jason J Marineau (16 out of 20 patents)

silverMedal Stephane Ciblat (15 out of 34 patents)

bronzeMedal Kevin Sprott (11 out of 21 patents)

4.  Anzhelika Kabro (10 out of 12 patents)

5.  Matthew Lucas Eaton (7 out of 7 patents)

6.  Darby Schmidt (7 out of 18 patents)

7.  Michael Bradley (7 out of 13 patents)

8.  Michael Robert McKeown (7 out of 12 patents)

9.  Melissa Leblanc (6 out of 9 patents)

10.  Serge Leger (6 out of 6 patents)

11.  Stephanie Roy (6 out of 8 patents)

12.  Dana K Winter (6 out of 8 patents)

13.  Tom Miller (6 out of 8 patents)

14.  Yi Zhang (5 out of 34 patents)

15.  M Arshad Siddiqui (5 out of 47 patents)


24 patents:

1. 12240869 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2025-03-04),
2. 11918592 - Inhibitors of cyclin dependent kinase 7 (CDK7) (2024-03-05),
3. 11753418 - Compounds for the modulation of Myc activity (2023-09-12),
4. 11447831 - Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists (2022-09-20),
5. 11311542 - Inhibitors of cyclin dependent kinase 7 (CDK7) (2022-04-26),
6. 11274103 - Compounds for the modulation of MYC activity (2022-03-15),
7. 11124527 - Compounds for the modulation of Myc activity (2021-09-21),
8. 11083728 - Compositions of cyclin dependent kinase 7 (CDK7) inhibitor (2021-08-10),
9. 11053552 - Methods of stratifying patients for treatment with retinoic acid receptor-α agonists (2021-07-06),
10. 11040981 - Pyrrolotriazine compounds and methods of inhibiting TAM kinases (2021-06-22),
11. 11040957 - Heteroaromatic compounds useful for the treatment of proliferative diseases (2021-06-22),
12. 10865206 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2020-12-15),
13. 10787444 - Compounds for the modulation of myc activity (2020-09-29),
14. 10738067 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2020-08-11),
15. 10697025 - Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists (2020-06-30),
Company Overview
Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, MA, focused on developing innovative therapies for cancer and other serious diseases. The company specializes in gene control and utilizes its proprietary platform to discover and develop medicines that target the underlying genetic drivers of disease. By leveraging insights from genomics and advanced technologies, Syros aims to transform the treatment landscape for patients with unmet medical needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Syros Pharmaceuticals, Inc. USPTO Patent Assignee Logo
24 Patents

#115 in Cambridge, MA

#834 in Massachusetts

#13,895 in US

#26,686 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Syros Pharmaceuticals, Inc.

Forward Citations = 61

54 inventors:

goldMedal Jason J Marineau (16 out of 20 patents)

silverMedal Stephane Ciblat (15 out of 34 patents)

bronzeMedal Kevin Sprott (11 out of 21 patents)

4.  Anzhelika Kabro (10 out of 12 patents)

5.  Matthew Lucas Eaton (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Syros Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/syros-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…